

## RECCE® Trademark Registered – Israel

**SYDNEY Australia, 12 April 2023:** Recce Pharmaceuticals Ltd (**ASX:RCE, FSE:R9Q**) (the **Company**), the Company developing a new class of Synthetic Anti-infectives, is pleased to announce it has been issued Trade Mark Registration for RECCE® from the Israeli Patent Office, Trademarks Department.

The International Trade Mark Registration No. 1289603, formally assigns Israeli Trademark No. 355216 for the RECCE® mark, classified under the following class(es) and specification(s):

### Class 5

- Antibiotics
- Antibiotics for human use
- Pharmaceutical preparations, namely mixed antibiotic preparations

The Israeli pharmaceutical and biotech market has a well-established reputation for its world-class research facilities and high spending in research and development, broad international reach and a market value reaching \$5.3 billion USD in 2021, which is expected to grow, with a high penetration rate of innovative medicines. Furthermore, the compound annual growth rate of the Israel pharmaceutical market from 2018 – 2021 was +8.56%.<sup>1</sup>

This newly registered trademark in **Israel** further strengthens the Company's intellectual property portfolio with those already registered in the biggest pharmaceutical markets in the world such as **Australia, USA, Europe, Japan, China** and most recently in **Hong Kong**.

Recce Pharmaceuticals Chief Executive Officer James Graham said, "We are thrilled to receive this addition to Recce's Intellectual Property portfolio. This trademark is a welcomed advance in supporting the Company's Israeli opportunities over the time ahead."

---

<sup>1</sup> Israel Pharmaceuticals Report - Q1 2023 2023, Fitch Solutions Group Limited, London.



This announcement has been approved for release by Recce Pharmaceuticals Board.

## About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: **RCE**, FSE: **R9Q**) is developing a new class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE<sup>®</sup> 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE<sup>®</sup> 435 as an orally administered therapy for bacterial infections; and RECCE<sup>®</sup> 529 for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.

The FDA has awarded RECCE<sup>®</sup> 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE<sup>®</sup> 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world's only synthetic polymer and sepsis drug candidate in development. RECCE<sup>®</sup> 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.

Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce's anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.



**recce.com.au**  
ACN 124 849 065

**Chief Executive Officer**  
James Graham  
Recce Pharmaceuticals Ltd  
james.graham@recce.com.au

**Australia**  
Andrew Geddes  
CityPR  
+61 408 677 734  
ageddes@citypublicrelations.com.au

### Media and Investor Relations

**USA**  
Jordyn Temperato  
LifeSci Communications  
jtemperato@lifescicomms.com

**Europe**  
Guillaume van Renterghem  
LifeSci Advisors  
gvanrenterghem@lifesciadvisors.com